BALAXI

Balaxi Pharmaceuticals Share PriceBalaxi Pharmaceuticals

₹423.45
7.5 (1.8%)
As on 10 December, 2023 | 22:27 BSE: NSE: BALAXIISIN: INE618N01014

Balaxi Pharmaceuticals Performance

Day Range

  • Low 414.00
  • High 425.00
₹ 423.45

52 Week Range

  • Low 399.95
  • High 670.00
₹ 423.45
  • Open Price414.00
  • Previous Close415.95
  • Volume3536

Start SIP in Balaxi Pharmaceuticals

Start SIP

Balaxi Pharmaceuticals Share Price

  • Over 1 Month 0.89%
  • Over 3 Month -10.02%
  • Over 6 Month -19.13%
  • Over 1 Year -26.39%

Balaxi Pharmaceuticals Key Statistics

P/E Ratio -40.9
PEG Ratio 0.3
Market Cap Cr 433
Price to Book Ratio 2.4
EPS 15.9
Dividend 0
Relative Strength Index 50.95
Money Flow Index 52.26
MACD Signal -2.49
Average True Range 14.75

Balaxi Pharmaceuticals Investment Rating

  • Master Rating:
  • Balaxi Pharmaceuticals has an operating revenue of Rs. 287.94 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 17% is great, ROE of 25% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 12 which is a POOR score indicating inconsistency in earnings, a RS Rating of 6 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Balaxi Pharmaceuticals Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 17253023282621
Operating Expenses Qtr Cr 16212520252217
Operating Profit Qtr Cr 1454444
Depreciation Qtr Cr 0000000
Interest Qtr Cr 0000000
Tax Qtr Cr 0111211
Net Profit Qtr Cr 1344454
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 115104
Operating Expenses Annual Cr 9184
Operating Profit Annual in Cr 1717
Depreciation Cr 10
Interest Annual Cr 00
Tax Annual Cr 65
Net Profit Annual Cr 1615
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr -79
Cash from Investing Activity Annual Cr -2-7
Cash from Financing Annual Activity Cr 26-2
Net Cash Flow Annual Cr 170
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 9258
Fixed Assets Annual Cr 113
Total Non Current Assets Annual Cr 3128
Total Current Assets Annual Cr 9954
Total Assets Annual Cr 13082
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 9058
ROE Annual % 1825
ROCE Annual % 2434
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2220
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 55668187868389
Operating Expenses Qtr Cr 44576871726978
Operating Profit Qtr Cr 1191315151411
Depreciation Qtr Cr 1010000
Interest Qtr Cr 0000000
Tax Qtr Cr 1232332
Net Profit Qtr Cr 14-4188151413
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 339284
Operating Expenses Annual Cr 280229
Operating Profit Annual in Cr 5750
Depreciation Cr 21
Interest Annual Cr 10
Tax Annual Cr 117
Net Profit Annual Cr 4648
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 634
Cash from Investing Activity Annual Cr -11-28
Cash from Financing Annual Activity Cr 260
Net Cash Flow Annual Cr 216
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 183113
Fixed Assets Annual Cr 196
Total Non Current Assets Annual Cr 4635
Total Current Assets Annual Cr 194141
Total Assets Annual Cr 240176
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 180113
ROE Annual % 2542
ROCE Annual % 3148
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1820

Balaxi Pharmaceuticals Technicals

EMA & SMA

Current Price
₹423.45
7.5 (1.8%)
pointer
  • Bullish Moving Average
  • ___
  • 9
  • Bearish Moving Average
  • ___
  • 7
  • 20 Day
  • ₹420.73
  • 50 Day
  • ₹429.92
  • 100 Day
  • ₹450.69
  • 200 Day
  • ₹478.12
  • 20 Day
  • ₹419.17
  • 50 Day
  • ₹427.07
  • 100 Day
  • ₹451.71
  • 200 Day
  • ₹494.91

Balaxi Pharmaceuticals Resistance and Support

PIVOT
₹420.82
Resistance
First Resistance 427.63
Second Resistance 431.82
Third Resistance 438.63
RSI 50.95
MFI 52.26
MACD Single Line -2.49
MACD -1.78
Support
First Resistance 416.63
Second Resistance 409.82
Third Resistance 405.63

Balaxi Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 3,536 285,108 80.63
Week 2,638 183,895 69.71
1 Month 2,881 192,050 66.65
6 Month 3,276 214,383 65.45

Balaxi Pharmaceuticals Result Highlights

Balaxi Pharmaceuticals Synopsis

NSE-Medical-Generic Drugs

Balaxi Pharmaceutica is involved in the business activities of Other specialized wholesale. Company’s Total Operating Revenue is Rs. 108.14 Cr. and Equity Capital is Rs. 10.18 Cr. for the Year ended 31/03/2023. Balaxi Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/09/1942 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L25191TG1942PLC121598 and registration number is 000045.
Market Cap 433
Sales 95
Shares in Float 0.30
No of funds 3
Yield
Book Value 4.68
U/D Vol ratio 0.6
LTDebt / Equity
Alpha -0.16
Beta 0.53

Balaxi Pharmaceuticals

Owner NameSep-23Jun-23May-23Mar-23
Promoters 71.22%71.22%71.22%71.57%
Mutual Funds
Insurance Companies
Foreign Portfolio Investors 18.58%18.58%18.58%18.66%
Financial Institutions/ Banks 0.03%0.03%0.03%0.03%
Individual Investors 6.62%6.57%6.48%5.95%
Others 3.55%3.6%3.69%3.79%

Balaxi Pharmaceuticals Management

Name Designation
Mr. Ashish Maheshwari Managing Director
Mrs. Minoshi Maheshwari Non Executive Director
Mrs. Purnima Singh Kamble Independent Director
Mr. M Srinivas Rao Independent Director
Mr. Gandhi Gamji Independent Director
Mr. Kunal M Bhakta Independent Director

Balaxi Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Balaxi Pharmaceuticals Corporate Action

Date Purpose Remarks
2023-11-02 Quarterly Results
2023-08-03 Quarterly Results
2023-05-29 Audited Results & Dividend
2023-02-01 Quarterly Results
2022-11-05 Quarterly Results

Balaxi Pharmaceuticals FAQs

What is Share Price of Balaxi Pharmaceuticals ?

Balaxi Pharmaceuticals share price is ₹423 As on 10 December, 2023 | 22:13

What is the Market Cap of Balaxi Pharmaceuticals ?

The Market Cap of Balaxi Pharmaceuticals is ₹433.2 Cr As on 10 December, 2023 | 22:13

What is the P/E ratio of Balaxi Pharmaceuticals ?

The P/E ratio of Balaxi Pharmaceuticals is -40.9 As on 10 December, 2023 | 22:13

What is the PB ratio of Balaxi Pharmaceuticals ?

The PB ratio of Balaxi Pharmaceuticals is 2.4 As on 10 December, 2023 | 22:13

Q2FY23